Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
Public ClinicalTrials.gov record NCT03522441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Clindamycin 1% Gel To Clindamycin 1% Gel (Greenstone LLC) and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.
Study identification
- NCT ID
- NCT03522441
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2018 (Actual)
- Primary completion
- Apr 22, 2019 (Actual)
- Completion
- Apr 22, 2019 (Actual)
- Last update posted
- Oct 5, 2020
2018 – 2019
United States locations
- U.S. sites
- 10
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 11 | Encino | California | 91436 | — |
| Site 10 | Sherman Oaks | California | 91403 | — |
| Site 1 | Brandon | Florida | 33511 | — |
| Site 4 | Miramar | Florida | 33027 | — |
| Site 5 | Miramar | Florida | 33027 | — |
| Site 2 | Tampa | Florida | 33069 | — |
| Site 3 | Tampa | Florida | 33618 | — |
| Site 12 | High Point | North Carolina | 27262 | — |
| Site 8 | El Paso | Texas | 79902 | — |
| Site 9 | El Paso | Texas | 79925 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03522441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03522441 live on ClinicalTrials.gov.